← Retour
U.S. FDA approves AbbVie's drug for Parkinson's disease
Source : The Hindu26 septembre 2026Score de confiance : 45%
The drug tavapadon, which AbbVie gained access to through its $8.7 billion acquisition of Cerevel Therapeutics in 2023, comes as a once-a-day pill